Published in
American Association for the Advancement of Science, Science Translational Medicine, 273(7), 2015
DOI: 10.1126/scitranslmed.aaa3634
Links
Tools
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Journal article published in 2015 by
Reina N. Fuji,
Michael Flagella,
Miriam Baca,
Marco A. S. Baptista,
Jens Brodbeck,
Bryan K. Chan,
Brian K. Fiske 
,
Lee Honigberg,
Adrian M. Jubb,
Paula Katavolos,
Donna W. Lee,
Sock-Cheng Lewin-Koh,
Tori Lin,
Xingrong Liu,
Shannon Liu
and other authors.
,
Lee Honigberg,
Adrian M. Jubb,
Paula Katavolos,
Donna W. Lee,
Sock-Cheng Lewin-Koh,
Tori Lin,
Xingrong Liu,
Shannon Liu
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
LRRK2 kinase inhibitors, under development for Parkinson’s disease, have an effect on type II pneumocytes in nonhuman primate lung, suggesting that pulmonary toxicity may be a critical safety liability.